306 related articles for article (PubMed ID: 22149368)
1. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.
Akanbi MO; Scarsi KK; Taiwo B; Murphy RL
Expert Opin Pharmacother; 2012 Jan; 13(1):65-79. PubMed ID: 22149368
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside and nucleotide reverse transcriptase inhibitors in children.
Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R
Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393
[TBL] [Abstract][Full Text] [Related]
3. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
4. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
5. The ideal nucleoside/nucleotide backbone.
Gallant JE
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S44-51. PubMed ID: 15319669
[TBL] [Abstract][Full Text] [Related]
6. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
[TBL] [Abstract][Full Text] [Related]
7. A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.
Lange J
Antivir Ther; 2001; 6 Suppl 3():45-54. PubMed ID: 11678472
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
9. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
10. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
11. The role of nucleoside and nucleotide reverse transcriptase inhibitor backbones in antiretroviral therapy.
Young B
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S13-20. PubMed ID: 15319665
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
Cihlar T; Ray AS
Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088
[TBL] [Abstract][Full Text] [Related]
13. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.
Wainberg MA; Brenner BG; Turner D
Antimicrob Agents Chemother; 2005 May; 49(5):1671-8. PubMed ID: 15855480
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
Wonganan P; Limpanasithikul W; Jianmongkol S; Kerr SJ; Ruxrungtham K
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):551-564. PubMed ID: 32508203
[TBL] [Abstract][Full Text] [Related]
15. Stavudine-based multiple agent combinations: initial studies and ongoing comparative trials.
Murphy RL
Antivir Ther; 1998; 3 Suppl 4():69-73. PubMed ID: 10723516
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review.
Hightower M; Kallas EG
Braz J Infect Dis; 2003 Feb; 7(1):7-15. PubMed ID: 12807687
[TBL] [Abstract][Full Text] [Related]
18. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
Martin A; Moore CL; Mallon PW; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA;
PLoS One; 2013; 8(10):e77138. PubMed ID: 24204757
[TBL] [Abstract][Full Text] [Related]
19. Separation methods for nucleoside analogues used for treatment of HIV-1 infection.
Pereira AS; Tidwell RR
J Chromatogr B Biomed Sci Appl; 2001 Nov; 764(1-2):327-47. PubMed ID: 11817036
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
